Establishment Labs (NASDAQ:ESTA) Trading 7.1% Higher - Here's What Happened

Key Points

• Establishment Labs Holdings Inc. (NASDAQ:ESTA) saw a significant increase in its stock price, trading up 7.1% to $39.45 during recent trading, despite an overall decline in trading volume.
• Analysts have varying opinions on the stock, with Canaccord Genuity setting a target at $60.00 and Citigroup raising their target to $47.00, indicating a “Moderate Buy” average rating.
• The company reported a quarterly EPS of ($0.57), slightly missing estimates, but with a revenue increase of 16.1% year-over-year, suggesting growth potential amidst negative net margins.

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) traded up 7.1% on Tuesday . The company traded as high as $39.42 and last traded at $39.45. 61,627 shares traded hands during trading, a decline of 88% from the average session volume of 503,004 shares. The stock had previously closed at $36.84.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Mizuho boosted their price objective on shares of Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Citigroup boosted their target price on shares of Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research note on Wednesday, July 9th. Wall Street Zen raised shares of Establishment Labs from a "sell" rating to a "hold" rating in a research note on Saturday. Canaccord Genuity Group began coverage on shares of Establishment Labs in a research note on Wednesday, August 20th. They issued a "buy" rating and a $60.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Establishment Labs in a research note on Friday, June 13th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $56.50.

Establishment Labs Trading Down 2.7%

The company's fifty day moving average is $40.24 and its two-hundred day moving average is $37.90. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -12.94 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The business had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. During the same quarter last year, the company posted ($0.62) EPS. Establishment Labs's quarterly revenue was up 16.1% compared to the same quarter last year. Establishment Labs has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of Establishment Labs by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company's stock worth $1,105,000 after acquiring an additional 299 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Establishment Labs by 5.2% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company's stock worth $257,000 after acquiring an additional 300 shares during the last quarter. Raymond James Financial Inc. increased its stake in shares of Establishment Labs by 0.4% in the 1st quarter. Raymond James Financial Inc. now owns 119,752 shares of the company's stock worth $4,886,000 after acquiring an additional 491 shares during the last quarter. Swiss National Bank increased its stake in shares of Establishment Labs by 1.3% in the 1st quarter. Swiss National Bank now owns 39,000 shares of the company's stock worth $1,591,000 after acquiring an additional 500 shares during the last quarter. Finally, CWM LLC increased its stake in shares of Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company's stock worth $93,000 after acquiring an additional 686 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company's stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.